BriaCell Therapeutics Corp. (NASDAQ: BCTX), the clinical-stage biotechnology company, recently reported the overall survival benefit of its ongoing advanced breast cancer study. The company released overall survival (OS) data of women under treatment of Bria-IMT™, the company’s lead candidate for monotherapy in breast cancer. Bria-IMT™ is used alongside checkpoint inhibitors like Incyte’s retifanlimab and pembrolizumab KEYTRUDA® of Merck & Co., Inc.
On Thursday’s trading session, BCTX closed $6.18, up 94.34%. BCTX soared 104% premarket on account of this update on OS data in advanced breast cancer women. The stock had doubled over twice on heavy volumes since it reported an upbeat breast cancer treatment update.
Tumor Grade Report
BriaCell Therapeutics Corp noted that the patients suffering from grade I and grade II tumors fetched clinical results and benefits from the use of BriaCell’s treatment. Body’s immune response is triggered with HLA (human leukocyte antigen) molecules cells on the surface. BriaCell’s treatment, or immunotherapy treatment, seems to show the most effective when HLA-type patients match the treatment. Bria-IMT™ match enables BriaCell in the potential identification of patients who are most likely to respond.
Top responders story
BriaCell Therapeutics has emphasized treatment’s positive response since September 19, 2019, and most recently, on January 13, 2020. The company reported that before BriaCell’s treatment, the responder was given 12 regimens with 16 agents, including 13 chemotherapies. They continue, despite all this deteriorated and left the tumor metastasize behind the left eye. Six months into the treatment of BriaCell, the orbital tumor was eliminated, and the woman survived for over 21 months, indicating a significant breakthrough and clinical benefit.
Meanwhile, the overall survival remained 7.2-9.8 months in women with metastatic breast cancer where two previous therapy attempts had failed.
BriaCell Therapeutics is skyrocketing on account of this positive overall survival data, with prominent responder having metastasized eye-bulging orbital tumor proving treatment effectiveness.